Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.
Acer Therapeutics in-licensed the clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist osanetant from Sanofi. MyoKardia regained global rights to all the programs that the company had inked with Sanofi.
The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.
Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.
A new method of analyzing images from CT scans can predict which patients are at risk of a heart attack years before occurrence, researchers say.
Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.
Former U.S. National Football League (NFL) athletes who bulked up before and during their professional careers have an increased risk of heart disease and other health problems compared with other players, researchers say.
With increased access to insurance under the Affordable Care Act (also known as Obamacare), fewer uninsured patients have been hospitalized for serious heart conditions, a U.S. study suggests.
Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.